켈스 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 한국투자파트너스, was filed 08 Aug 2025.
켈스: what insiders have been doing
켈스 belongs to the Health Care sector. Filings by its managers are published through DART (FSS). Nothing new has been filed by managers of 켈스 in twelve months, the latest record being from 8 August 2025.
Elsewhere in the same sector, our signals recently picked up insider purchases at Relmada Therapeutics, Inc. and MAIA Biotechnology, Inc. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleFinancial data
· cache
- 222,222 sharesKRXDART:20250808000620Canonical exit: 22 Oct 2025 (T+90)
- ●Executives0DART
- 222,222 sharesKRXDART:20211208000091Canonical exit: 8 Mar 2022 (T+90)
- 222,222 sharesKRXDART:20211207000504Canonical exit: 7 Mar 2022 (T+90)
- ShareKRXDART:20211207000408Canonical exit: 7 Mar 2022 (T+90)
- 222,222 sharesKRXDART:20211207000404Canonical exit: 7 Mar 2022 (T+90)
- ShareKRXDART:20211207000303Canonical exit: 7 Mar 2022 (T+90)
- 222,222 sharesKRXDART:20211207000365Canonical exit: 7 Mar 2022 (T+90)
- ShareKRXDART:20211207000339Canonical exit: 7 Mar 2022 (T+90)
- ShareKRXDART:20211207000442Canonical exit: 7 Mar 2022 (T+90)
- 222,222 sharesKRXDART:20211206000366Canonical exit: 6 Mar 2022 (T+90)
11 of 11 declarations
About 켈스
켈스 is a company operating in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on the development and commercialization of innovative pharmaceutical products.
